Table 4.
Infectivity in mice of purified, cryopreserved PySPZ administered IV or ID*
| Intravenous (IV) | Intradermal (ID) | ||||||
|---|---|---|---|---|---|---|---|
| No. of PySPZ Injected | Number of mice | Proportion infected | No. of PySPZ injected | Number of mice | Proportion infected | ||
| Infected | Injected | Infected | Injected | ||||
| 33 | 2 | 5 | 40% | 200 | 2 | 5 | 40% |
| 100 | 1 | 5 | 20% | 600 | 3 | 5 | 60% |
| 300 | 5 | 5 | 100% | 1800 | 3 | 5 | 60% |
| 900 | 5 | 5 | 100% | 5400 | 4 | 5 | 80% |
| 80% infectious dose = 257 PySPZ | 80% infectious dose = 5871 PySPZ | ||||||
| 100% infectious dose = 528 PySPZ | 100% infectious dose = N/A | ||||||
*
Purified, cryopreserved PySPZ were injected IV in the tail vein or ID at the base of the tail of 6–8 week old BALB/c. Infection was determined by examination of blood smears on Days 7 and 14 after inoculation. The 80% and 100% infectious doses were calculated using CurveExpert version 1.4.